Making a difference for patients with
IgA nephropathy is a chronic kidney disease that often progresses to renal failure, as there is no disease-specific treatment. Our mission is to develop assays for biomarkers of IgA nephropathy with diagnostic and/or prognostic value that will enable development and testing of future disease-specific therapies. Our vision is that Reliant Glycosciences biomarker assays will provide an avenue for early identification of patients with IgA nephropathy, enable development of successful treatment options, and offer a tool to monitor responses to therapy.
ABOUT RELIANT GLYCOSCIENCES
Reliant Glycosciences, LLC was founded in 2015 as a spin-out company from the University of Alabama at Birmingham based on technology developed in the laboratory of Dr. Jan Novak in the Department of Microbiology. Dr. Novak's research group discovered autoantibodies in patients with IgA nephropathy specific for aberrantly glycosylated IgA1, galactose-deficient in some of the hinge-region O-glycans. These autoantibodies drive formation of pathogenic immune complexes some of which deposit in the kidneys to incite tissue injury. Serum levels of these autoantibodies predict disease progression. These discoveries led to the development of biomarker assays for IgA nephropathy that have the potential to diagnose and monitor the disease.
In partnership with UAB, Reliant Glycosciences, LLC licensed this technology to develop the assays for commercial use.
The expertise at Reliant Glycosciences, LLC provides consulting and research services for IgA nephropathy in the following areas:
Consulting in design of clinical trials for treatment of patients with IgA nephropathy.
Testing for disease-specific biomarkers of IgA nephropathy including:
We’re happy to hear from you. Contact us today to learn more about our assays and expertise and how you can benefit from working with us.
400 Riverhills Business Park
Birmingham, AL 35242